$NNOX

Nanox.AI, a subsidiary of Nano-X Imaging Ltd. (NNOX), signed a 3-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution. Separately, it partnered with Intel to optimize its AI framework for local hospital hardware. The company aims to leverage additional anatomical data from CT scans to support clinical evaluations. According to Nanox, 86,000 vertebral fragility fractures occur annually in the UK, many undiagnosed.

Nanox reports Q2 revenue of $4.2 million, highlighting its integrated imaging ecosystem. The company aims to expand access to 3D imaging and diagnostics with its Nanox.ARC system, which is FDA-cleared. Nanox addresses global disparities in imaging technology access, with a focus on lower adoption barriers.

Nano-X Imaging Ltd. (NNOX) is developing an integrated medical imaging platform combining hardware, AI, and cloud software for early disease detection. The company reported Q1 2026 revenue of $4.3M, up from $2.8M a year earlier. It is expanding through partnerships with healthcare organizations and licensing its technology.

Suesskind Dan S purchased 60,000 shares of Nano-X Imaging Ltd. (NNOX) at an average of $0.76 ($0.75–$0.76) across 2 trades on 2026-09-14.

Nano-X Imaging (NNOX) reported Q2 revenue growth of 37% YoY to $4.2M, but also a $40.7M impairment charge and a 50% cash reduction in six months. The company plans to cut costs and outsource manufacturing. First reimbursement payments from a Philadelphia site ranged from $200 to $700 per claim. Cash reserves fell to $31.4M, raising concerns about the company's going concern status.

Nanox (NASDAQ:NNOX) reported Q2 2026 revenue of $4.2M, up 37% YoY, driven by its acquired Nanox Health IT unit. However, a $40.7M impairment charge widened its GAAP net loss to $55.5M. Cash declined to $31.4M, though the company raised $8.5M post-quarter. Nanox aims to continue fundraising amid ongoing losses and restructuring efforts.

Nano X Imaging Ltd (NNOX) reported a 37% year-over-year revenue increase in Q2 2026, driven by growth in teleradiology services and new partnerships. The company also announced operational streamlining and cost reductions. However, NNOX recorded a $40.7 million impairment charge, a significant decrease in cash position, and a widened net loss of $55.5 million. Management expects revenue traction in the coming months and potential market expansion due to new reimbursement codes.

Nano-X Imaging Ltd. (NNOX) reported a wider Q1 2026 loss of $14.27M ($0.20/share) vs. $13.24M ($0.21/share) in Q1 2025. Adjusted net loss was $11.13M ($0.16/share) vs. $9.24M ($0.15/share). Revenue rose to $4.31M from $2.82M. Shares fell 20.82% to $0.7370.

Nano-X Imaging Ltd. (NNOX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates Management to host conference call and webcast on Wednesday, September 9, 2026 at 8:30 AM ET PETACH TIKVA, Israel — September 9, 2026 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or

Nano-X Imaging (NNOX) expanded its U.S. distribution for Nanox.ARC, a 3D imaging system, via a deal with Associated X-Ray Imaging. The agreement aims to boost access in New England and supports Nanox's U.S. commercial strategy. NNOX shares are up 1.02% in premarket trading at $0.72.